Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Conditions
Brief summary
This phase II clinical trial is studying the how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving veliparib with chemotherapy may kill more tumor cells. Filgrastim or pegfilgrastim may cause the body to make more blood cells and help it recover from the side effects of chemotherapy.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the antitumor activity (objective response rate by RECIST 1.1) of ABT-888 (veliparib) 10 mg administered orally twice a day on days 1 to 5 with topotecan (topotecan hydrochloride) 0.6 mg/m\^2 administered IV once daily on days 1 to 5 of each cycle in patients with persistent or recurrent carcinoma of the cervix. II. To determine the nature and degree of toxicity of ABT-888 and topotecan in patients with persistent or recurrent carcinoma of the cervix. SECONDARY OBJECTIVES: I. To determine the duration of progression-free survival and overall survival. TERTIARY OBJECTIVES: I. To determine whether evidence of an interaction exists between study treatments and tumor expression of poly(ADP-ribos)ylation of E2 protein, E6/E7 proteins, and p53R2 in relation to progression-free and overall survival or metastasis. (Translational) II. To explore the association between methylation of FanCF and BRCA in pre-treatment tumor samples and pre- and post-treatment biopsy samples and response, progression-free and overall survival of patients, and/or metastasis. (Translational) OUTLINE: Patients receive veliparib orally (PO) twice daily and topotecan hydrochloride intravenously (IV) over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim subcutaneously (SC) beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Tumor tissue samples may be collected periodically for translational studies. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Interventions
BIOLOGICALFilgrastim
Given SC
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPegfilgrastim
Given SC
DRUGTopotecan Hydrochloride
Given IV
DRUGVeliparib
Given PO
Sponsors
NRG Oncology
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have persistent or recurrent squamous cell carcinoma, adenosquamous carcinoma, adenocarcinoma or non-squamous cell carcinoma of the cervix with documented disease progression; histological documentation of the original primary tumor is required via the pathology report * All patients must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI * Patient must have at least one target lesion to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy * Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population * Patients must have a GOG performance status of 0, 1, or 2 * Recovery from effects of recent surgery, radiotherapy, or chemotherapy * Patients should be free of active infection requiring antibiotics * Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted * Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted (non-cytotoxic) therapy and immunologic agents must be discontinued at least three weeks prior to registration; all side effects must have resolved to =\< grade 1 or stabilized, prior to enrolling on this study * Any prior radiation therapy must be completed at least 4 weeks prior to registration * Patients MUST have had one prior systemic chemotherapeutic regimen for management of advanced, metastatic, or recurrent squamous or non-squamous cell carcinoma of the cervix; chemotherapy administered concurrent with primary radiation is not counted as a systemic chemotherapy regimen (e.g.; weekly cisplatin); adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles) * Patients who are registered during the safety lead-in portion of this protocol are required to have prior pelvic radiation * Patients must have NOT received more than one previous cytotoxic chemotherapy regimen (either with single or combination cytotoxic drug therapy) * Patients are allowed to receive, but are not required to receive, biologic/targeted (non-cytotoxic) therapy as part of their one prior systemic chemotherapeutic regimen; patients are allowed to receive, but are not required to receive, biologic/targeted (non-cytotoxic) therapy for management of recurrent or persistent disease * Patients MUST not be eligible for further curative intent surgical or pelvic radiation treatment for management of recurrent or persistent disease as determined by treating physicians * Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl * Platelets greater than or equal to 100,000/mcl * Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) * Bilirubin less than or equal to 1.5 x ULN * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN * Alkaline phosphatase less than or equal to 2.5 x ULN * Neuropathy (sensory and motor) less than or equal to grade 1 * Patients must have signed an approved informed consent and authorization permitting release of personal health information * Patients must meet pre-entry requirements * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients must have the ability to swallow pills whole
Exclusion criteria
* Patients are excluded who have had prior therapy with ABT-888 (veliparib), poly (ADP)-ribose polymerase inhibitors, or topotecan * Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy * Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of cervical cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease * Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of cervical cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease * Patients with seizures or history of seizures are ineligible * Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, any CNS metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study, are ineligible; patients with CNS metastases must be stable for \> 3 months after treatment and off steroid treatment prior to study enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response | Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicted based on symptoms or physical signs suggestive of progressive disease. The average time was 2.3 months | Complete and Partial Tumor Response as Assessed by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation. |
| Number of Patients With Dose-limiting Toxicities (in Safety lead-in) | Up to 21 days | A dose-limiting toxicity (DLT) is assessed by NCI CTCAE v4, occurring during cycle 1 of therapy.: A dose-limiting toxicity (DLT) is defined as either hematologic or non-hematologic toxicity assessed by NCI CTCAE v4, occurring during cycle 1 of therapy, which cause any of the following: For hematologic toxicity - dose delay of greater than 2 weeks due to failure to recover counts, Treatment related febrile neutropenia, grade 4 neutropenia lasting \>7 days, treatment related grade 4 thrombocytopenia or clinically significant bleeding with grade 3 thrombocytopenia. For non-hematologic toxicity; study treatment related grade 3 or 4 non-hematological toxicity (excluding anorexia, constipation, fatigue, hypersensitivity/allergic reaction to one of the study drugs, nausea & vomiting, and grade 3 dehydration), grade 4 nausea and vomiting for \>48 hours despite maximum medical management, electrolyte imbalance of \> or equal to grade 3 that can be replaced within 48 hours; any drug related death |
| Adverse Events (Grade 3 or Higher) During Treatment Period | During treatment period and up to 30 days after stopping the study treatment.The average of study treatment time was 2.3 months. | Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up. | Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is defined as at least a 20% increase in the sum of the longest dimensions (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions, or global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or death due to disease without prior objective documentation of progression. |
| Overall Survival | From study entry to death or last contact, up to 5 years of follow-up. | Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
| Duration of Objective Response | Every other cycle for first 6 months; then every 3 months until disease progression confirmed; and at any other time if clinically indicated based on symptoms or signs suggestive of progressive disease.The average of study treatment time was 2.3 months. | Duration of objective response is defined as the duration from the time measurement criteria is met for partial or complete response by RECIST 1.1, whichever is first recorded, until the first date the recurrent or progressive disease is objectively documented. Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation. |
Countries
United States
Participant flow
Recruitment details
The study was activated on 2/7/2011 and closed to accrual on 1/17/2013.
Participants by arm
| Arm | Count |
|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim ABT-888 10mg administered orally twice a day on days 1 to 5 of each cycle. Topotecan administered at 0.6 mg/m2 intravenously once daily on days 1 to 5 of each cycle. Each cycle of treatment repeats every 21 days until disease progression or adverse effects prohibit further treatment. All patients will receive filgrastim or pegfilgrastim beginning with cycle 1. | 27 |
| Total | 27 |
Baseline characteristics
| Characteristic | ABT-888, Topotecan and Filgrastim or Pegfilgrastim |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 25 Participants |
| Age, Continuous | 49.8 years STANDARD_DEVIATION 10.1 |
| Region of Enrollment United States | 27 participants |
| Sex: Female, Male Female | 27 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 27 / 27 |
| serious Total, serious adverse events | 16 / 27 |
Outcome results
Primary
Adverse Events (Grade 3 or Higher) During Treatment Period
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.
Time frame: During treatment period and up to 30 days after stopping the study treatment.The average of study treatment time was 2.3 months.
Population: Eligible and treated patients - No statistical analysis provided for adverse events (grade 3 or higher) during treatment period.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Leukopenia | 6 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Thrombocytopenia | 12 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Neutropenia | 5 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Anemia | 16 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Other Investigations | 4 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Cardiac Disorders | 1 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Gastrointestinal Disorders | 7 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | General Disorders & administration site conditions | 5 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Infections and Infestations | 4 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Metabolism and nutrition disorders | 3 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Musculoskeletal and connective tissue disorders | 5 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Neoplasms benign, malignant and unspecified | 1 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Nervous system disorders | 1 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Renal and urinary disorders | 0 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Reproductive system and breast disorders | 2 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Respiratory, thoracic and mediastinal disorders | 4 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Surgical and medical procedures | 1 Participants |
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Adverse Events (Grade 3 or Higher) During Treatment Period | Vascular disorders | 3 Participants |
Primary
Number of Patients With Dose-limiting Toxicities (in Safety lead-in)
A dose-limiting toxicity (DLT) is assessed by NCI CTCAE v4, occurring during cycle 1 of therapy.: A dose-limiting toxicity (DLT) is defined as either hematologic or non-hematologic toxicity assessed by NCI CTCAE v4, occurring during cycle 1 of therapy, which cause any of the following: For hematologic toxicity - dose delay of greater than 2 weeks due to failure to recover counts, Treatment related febrile neutropenia, grade 4 neutropenia lasting \>7 days, treatment related grade 4 thrombocytopenia or clinically significant bleeding with grade 3 thrombocytopenia. For non-hematologic toxicity; study treatment related grade 3 or 4 non-hematological toxicity (excluding anorexia, constipation, fatigue, hypersensitivity/allergic reaction to one of the study drugs, nausea & vomiting, and grade 3 dehydration), grade 4 nausea and vomiting for \>48 hours despite maximum medical management, electrolyte imbalance of \> or equal to grade 3 that can be replaced within 48 hours; any drug related death
Time frame: Up to 21 days
Population: The first 6 eligible and treated patients who completed the 1st cycle of study treatment or had a DLT prior to completing the first cycle of study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Number of Patients With Dose-limiting Toxicities (in Safety lead-in) | 1 participants |
Primary
Tumor Response
Complete and Partial Tumor Response as Assessed by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation.
Time frame: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicted based on symptoms or physical signs suggestive of progressive disease. The average time was 2.3 months
Population: Eligible and Treated Patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Tumor Response | 7.4 percentage of participants |
Secondary
Duration of Objective Response
Duration of objective response is defined as the duration from the time measurement criteria is met for partial or complete response by RECIST 1.1, whichever is first recorded, until the first date the recurrent or progressive disease is objectively documented. Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation.
Time frame: Every other cycle for first 6 months; then every 3 months until disease progression confirmed; and at any other time if clinically indicated based on symptoms or signs suggestive of progressive disease.The average of study treatment time was 2.3 months.
Population: Eligible and Treated Patients with objective response
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Duration of Objective Response | 5.3 Months |
Secondary
Overall Survival
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
Time frame: From study entry to death or last contact, up to 5 years of follow-up.
Population: Eligible and Treated Patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Overall Survival | 8.2 months |
Secondary
Progression-free Survival
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is defined as at least a 20% increase in the sum of the longest dimensions (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions, or global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or death due to disease without prior objective documentation of progression.
Time frame: From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.
Population: Eligible and Treated Patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ABT-888, Topotecan and Filgrastim or Pegfilgrastim | Progression-free Survival | 2.0 months |